M&As this week: Otsuka, Photonamic, Boston Scientific

4 May 2018 (Last Updated May 4th, 2018 11:21)

Otsuka Pharmaceutical Factory (OPF) has acquired all the shares of Lilium Otsuka Co Ltd held by Otsuka Medical Devices, through a share purchase agreement.

Otsuka Pharmaceutical Factory (OPF) has acquired all the shares of Lilium Otsuka Co Ltd held by Otsuka Medical Devices, through a share purchase agreement.

Lilium Otsuka will operate as a wholly owned subsidiary of OPF, following the acquisition.

OPF is a provider of parenteral nutrition products, while Lilium is a developer and manufacturer of medical devices.

All the companies involved in the transaction are based in Japan.

Photonamic GmbH and Co KG plans to acquire NX Development Corp (NXDC) for an undisclosed sum.

NXDC will operate as a wholly owned subsidiary of Photonamic.

Based in Germany, Photonamic is engaged in the research and development of 5-aminolevulinic acid and other photosensitisers for therapeutic and diagnostic applications, while NXDC is a life sciences company based in the US.

“The acquirer company will continue to support the target company’s operations and the commercialisation of Lombard’s stent graft technologies.”

The transaction will enable both the acquirer and target companies to bring real-time imaging agent Gleolan to the neurosurgical community.

Boston Scientific has completed the acquisition of NxThera and its minimally invasive Benign Prostatic Hyperplasia (BPH) therapy, Rezūm System, for $406m.

The deal was originally signed in March involving $306m in upfront payment and the remaining $100m to be paid over a four-year period.

NxThera will become part of the Boston Scientific’s urology and pelvic health business, following the acquisition.

Based in the US, Boston Scientific is a manufacturer and marketer of medical devices, while NxThera, also based in the US, is the developer of the Rezûm System.

China-based MicroPort Scientific Corp has purchased the shares of Lombard’s subsidiaries, Lombard Medical Limited, and Lombard Medical Technologies GmbH under the UK bankruptcy law.

The acquirer company will continue to support the target company’s operations and the commercialisation of Lombard’s stent graft technologies, Aorfix and Altura, as part of the transaction.

Microport will also continue to obtain China Food and Drug Administration (CFDA) approval for Lombard’s products.

Lombard will retain its manufacturing facility in Didcot, UK, and plans to continue the enrolment of post-market ALTITUDE clinical registry for Altura in the UK and German markets.

Lombard Medical Limited and Lombard Medical Technologies GmbH are medical technology companies based in the UK and Germany respectively.

US-based respiratory devices manufacturer Vyaire Medical Inc has completed the acquisition of Acutronic Medical Systems AG through the medical technology firm, Becton Dickinson and Co.

Vyaire Medical has simultaneously signed an agreement to acquire IMTmedical AG.

Acutronic Medical Systems and IMTmedical are both medical device companies based in Switzerland.

The acquisitions will enable Vyaire to expand its product portfolio and technological capabilities.